RT Journal Article
SR Electronic
T1 Current etiology of hypertension in European children – role of serum uric acid
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.12.12.24318959
DO 10.1101/2024.12.12.24318959
A1 Obrycki, Łukasz
A1 Skoczyński, Krzysztof
A1 Sikorski, Maksymilian
A1 Koziej, Jan
A1 Mitoraj, Kacper
A1 Pilip, Jakub
A1 Pac, Michał
A1 Feber, Janusz
A1 Litwin, Mieczysław
YR 2024
UL http://medrxiv.org/content/early/2024/12/13/2024.12.12.24318959.abstract
AB Background While hypertension (HT) in pediatric patients is often secondary (SH), recent trends show a rise in primary hypertension (PH), which is associated with an increasing global prevalence of obesity. Our study aimed to assess the etiology of HT and predictors of PH in a large European cohort of children referred for HT based on office blood pressure (BP) measurements.Methods We performed retrospective analysis of 2008 children aged 0–18 years (12.3 ± 4.9 years) diagnosed with HT. Patients were classified into white coat hypertension (WCH), PH, or SH groups based on office BP and 24-hour ambulatory BP monitoring (ABPM). Clinical, anthropometric, and biochemical data were collected to differentiate PH and SH and to identify predictors of PH.Results Out of 2008 patients included in the analysis, HT was confirmed in 1452 patients (556 were classified as WCH). Of 1452 patients with HT: 42.8% had PH, while 57.2% had SH, mainly secondary to renal parenchymal disease (33.2% of SH patients), post-kidney transplant HT (23.1%), aortic coarctation (15.9%) and renovascular HT (13.8%). However, PH started to be the dominant cause of HT after 13 years of age and was diagnosed in 59.1% of 13–18-year-old patients with confirmed HT. Age ≥ 13 years, obesity (BMI-SDS ≥1.65), and serum uric acid ≥ 5.5 mg/dL were identified as significant PH predictors.Conclusions Our study provides valuable insights into the current etiology of pediatric HT and highlights the role of uric acid level assessment in the diagnosis of PH in children.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was funded by The Children's Memorial Health Institute intramural grant M22/2022.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Bioethics Committee of the Children's Memorial Health Institute.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData available on request from the authors